The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2018 | Drug cost vs. toxicity in MM
Hareth Nahi, MD, of the Karolinska Institutet, Stockholm, Sweden, discusses the association between drug cost and toxicity at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. In multiple myeloma (MM), he uses the example of carfilzomib and bortezomib. While carfilzomib yields fewer side effects, it is more expensive. Dr Nahi explains how the cost of treating drug side effects, combined with the increased quality of life associated with carfilzomib, makes it the clear drug of choice.
